Cargando…

Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression

OBJECTIVE: To assess the clinical efficacy of osimertinib in patients with advanced non-small cell lung cancer and its effect on serum carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) expression. METHODS: Between July 2018 and January 2020, 80 patients with advanced non-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huanyuan, Zhou, Xiangwu, Wang, Zhaozhen, Lu, Tianzhu, Li, Baoliang, Jiang, Sicong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159882/ https://www.ncbi.nlm.nih.gov/pubmed/35664943 http://dx.doi.org/10.1155/2022/3032087

Ejemplares similares

Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag
por: He, Linghui, et al.
Publicado: (2022)

Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Zhu, Yanxing, et al.
Publicado: (2023)

The diagnostic value of serum CEA, NSE and MMP-9 for on-small cell lung cancer
por: Xu, Liu, et al.
Publicado: (2016)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer
por: Zhang, Zhi-Hui, et al.
Publicado: (2015)

Diagnosis Value of Combined Detection of Serum SF, CEA and CRP in Non-Small Cell Lung Cancer
por: Zhou, Jing, et al.
Publicado: (2020)

The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels
por: Xie, Hai-Lun, et al.
Publicado: (2019)

Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome
por: Jiao, Zonglin, et al.
Publicado: (2021)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

Significance of CEA and VEGF as Diagnostic Markers of Colorectal Cancer in Lebanese Patients
por: Dbouk, Hashem A., et al.
Publicado: (2007)

Simultaneous Detection of VEGF and CEA by Time-Resolved Chemiluminescence Enzyme-Linked Aptamer Assay
por: Man, Jin, et al.
Publicado: (2020)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022)

Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
por: de Jong, Corine, et al.
Publicado: (2020)

An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
por: Shi, Yue, et al.
Publicado: (2022)

Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
por: Gao, Zhiqiang, et al.
Publicado: (2020)

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer
por: Zheng, Jie, et al.
Publicado: (2022)

Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study
por: Arrieta, Oscar, et al.
Publicado: (2013)

Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic
por: Lakkunarajah, Suganija, et al.
Publicado: (2023)

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
por: Mu, Yuxin, et al.
Publicado: (2019)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.
por: Pedley, R. B., et al.
Publicado: (1989)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study
por: Yang, Xue, et al.
Publicado: (2021)

The Clinical Efficacy of Chemotherapy Combined with Traditional Chinese Medicine in the Treatment of Cervical Cancer and Its Influence on Cellular Immunity, Serum CEA, and TNF-α
por: Zhao, Qiannan, et al.
Publicado: (2022)

The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer
por: Zhao, Tongwei, et al.
Publicado: (2021)

50 years of the physics of the infinitely small at the CEA
Publicado: (1996)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis
por: He, Guangsi, et al.
Publicado: (2019)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Relationship of serum CEA levels to tumour size and CEA content in nude mice bearing colonic-tumour xenografts.
por: Lewis, J. C., et al.
Publicado: (1981)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
por: Wen, Lei, et al.
Publicado: (2023)

Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer
por: Lai, Yanzhen, et al.
Publicado: (2018)

The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib
por: Wang, Yun, et al.
Publicado: (2023)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
por: Cheng, Yuan, et al.
Publicado: (2021)

The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
por: Pan, Guoqiang, et al.
Publicado: (2021)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e3nn95em27c0mqqga5fqnhtect